Upper Blepharoplasty Under Anticoagulant or Antiplatelet Therapy: Is Safety Still a Concern?
Complication rates similar with or without continued blood thinners for eyelid surgery
Upper Blepharoplasty Under Anticoagulant or Antiplatelet Therapy: Is Safety Still a Concern?
Dermatochalasis is defined as a skin excess in the upper or lower eyelid which may be associated with orbital fat prolapse, lacrimal gland prolapse, and involutional blepharoptosis.
This study aimed to investigate the safety of upper blepharoplasty in patients receiving antithrombotic therapy.
The cohort was stratified into two groups: a study group of 100 patients on anticoagulant/antiplatelet therapy (including aspirin, warfarin, and apixaban) and a control group of 292 patients not on such therapy.
checked complications after surgery, similar with either choice
Baseline characteristics differed significantly between groups, with patients on anticoagulant/antiplatelet therapy being older and having higher comorbidity rates.
Notably, no major bleeding events occurred.
Patient-reported and surgeon-assessed satisfaction scores were high and similar between groups.
On multivariable logistic regression analysis, no variable was identified as a significant independent predictor of complications; however, hypertension demonstrated the highest odds ratio (OR 2.9, 95% CI 0.29-28.56, p=0.370).
Upper blepharoplasty appears to be safely performed in carefully selected patients receiving anticoagulant or antiplatelet therapy.
In this retrospective cohort, continuation of antithrombotic therapy was not associated with an increased rate of detected complications compared with controls.
These findings support the feasibility of maintaining therapy in appropriately selected cases, although larger prospective studies are required to confirm these observations.